Cardiff University received government funding to discover what was causing the clotting. Researchers soon realized that people suffering clots had extra antibodies that were attacking “platelet factor four”.
“So what we showed in this paper is that adenoviruses which is the shell of the virus is able to form an interaction with another protein which naturally exists in human blood called platelet factor 4,” said Dr. Alexander Baker, researcher explained.
“It’s really critical to fully investigate the vector-host interactions of the vaccine at a mechanistic level,” said Dr. Abhishek Singharoy, a scientist at ASU.
AstraZeneca isn’t denying the report.
“Although the research is not definitive, it offers interesting insights and AstraZeneca is exploring ways to leverage these findings as part of our efforts to remove this extremely rare side effect,” a spokeswoman said.
The Telegraph also reported:
Professor Alan Parker, one of the researchers at Cardiff University, told BBC News: “The adenovirus has an extremely negative surface, and platelet factor four is extremely positive and the two things fit together quite well.”
He added: “We’ve been able to prove the link between the key smoking guns of adenoviruses and platelet factor four.
“What we have is the trigger, but there’s a lot of steps that have to happen next.”
Before the report was made public the United Kingdom had already ceased offering the AstraZeneca vaccine to people under 40 because of health risks.